Are postprandial triglyceride and insulin abnormalities neglected cardiovascular risk factors in type 2 diabetes?

European Journal of Clinical Investigation, Supplement

Volumn 30, Issue 2, 2000, Pages 12-18

  Golay, A ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BIGUANIDE; CIPROFIBRATE; FENOFIBRATE; GLUCOSE; INSULIN; METFORMIN; MIGLITOL; SULFONYLUREA; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CONFERENCE PAPER; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; SYNDROME X;

EID: 0033865341     PISSN: 0960135X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.30.s2.3.x     Document Type: Conference Paper

References (54)

1. 1 Shantaram V. Pathogenesis of atherosclerosis in diabetes and hypertension. Clin Exp Hypertens 1999;21:69-77.
2. 2 Betteridge DJ. Diabetic dyslipidaemia. Eur J Clin Invest 1999;29(Suppl. 2):12-16.
3. 3 Golay A, Felber JP. Evolution from obesity to diabetes. Diabetes Metab 1994;20:3-14.
4. 4 Carpentier A, Lewis GF. Diabetes mellitus and dyslipidaemia: a rational therapeutic strategy. Can J Diabetes Care 1998;22:28-38.
5. 5 Horowitz BS, Ginsberg HN. Dyslipidaemia. In: De Fronzo RA, editor. Current Therapy of Diabetes Mellitus. St Louis, MO: Mosby;1998.p.123-33.
6. 6 Lewis GF, Uffelman KD, Szeto LW, et al. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 1995;95:158-66.
7. 7 Bioletto S, Golay A, Munger R, et al. Acute hyperinsulinaemia and very low density and low density lipoprotein subfractions in obese subjects. Am J Clin Nutrit 2000;71:443-49.
8. 8 Chen Y-DI, Golay A, Swislocki ALM, et al. Resistance to insulin suppression of plasma free fatty acid concentrations and insulin stimulation of glucose uptake in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987;64:17-21.
9. 9 Golay A, Swislocki ALM, Chen Y-DI, et al. Relationships between plasma free fatty acid concentration, endogenous glucose production, and fasting hyperglycaemia in normal and non-insulin-dependent diabetic individuals. Metab Clin Exp 1987;36:692-96.
10. 10 Haffner SM, Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med 1997;103:152-62.
11. 11 Haffner SM, Valdez RA, Hazuda HP, et al. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992;41:715-22.
12. 12 Mykkanen L, Kuusisto J, Haffner SM, et al. Hyperinsulinaemia predicts multiple atherogenic changes in lipoproteins in elderly subjects. Arterioscler Thromb 1994;14:518-26.
13. 13 Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
14. 14 DeFronzo RA, Ferrannini E. Insulin resistance. A multi-faceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
15. 15 Haffner SM, D'Agostino RJ, Mykkanen L, et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1999;22:562-68.
16. 16 Hanefeld M, Leonhardt W. Das metabolische syndrom. Gesundheitwesen 1981;36:545-51.
17. 17 Taskinen MR. Insulin resistance and lipoprotein metabolism. Curr Opin Lipidol 1995;6:153-60.
18. 18 Criqui MH. Triglycerides and cardiovascular disease. A focus on clinical trials. Eur Heart J 1998;19 (Suppl. A):A36-A39.
19. 19 Sattar N, Packard CJ, Petrie JR. The end of triglycerides in cardiovascular risk assessment? Rumours of death are greatly exaggerated. BMJ 1998;317:553-54.
20. 20 Lamarche B, Lemieux I, Després JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, pathophysiology and therapeutic areas. Diabetes Metab 1999;25:199-211.
21. 21 Fontbonne AM, Eschwège E. Insulin and cardiovascular disease. Paris Prospective Study. Diabetes Care 1991;14:461-69.
22. 22 Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM. The Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-83.
23. 23 Sharrett AR, Chambless LE, Heiss G, et al. Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vase Biol 1995;15:2122-29.
24. 24 Axelsen M, Smith U, Eriksson JW, et al. Postprandial hypertriglyceridaemia and insulin resistance in normoglycaemic first-degree relatives of patients with type 2 diabetes. Ann Intern Med 1999;131:27-31.
25. 25 Lewis GF, O'Meara NM, Soltys PA, et al. Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. J Clin Endocrinol Metab 1991;72:934-44.
26. 26 Patsch JR, Miesenbock G, Hopferwieser T, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb Vasc Biol 1992;12:1336-45.
27. 27 Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter and risk of myocardial infarction. JAMA 1999;276:882-88.
28. 28 Lefebvre PJ, Scheen AJ. The postprandial state and risk of cardiovascular disease. Diabet Med 1999;15; (Suppl. 4):S63-S68.
29. 29 Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979;60:473-85.
30. 30 Ryu JE, Howard G, Craven TE, et al. Postprandial triglyceridemia and carotid atherosclerosis in middle-aged subjects. Stroke 1992;23:823-28.
31. 31 Karpe F, Steiner G, Uffelman K, et al. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994;106:83-97.
32. 32 Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-18.
33. 33 European Diabetes Policy Group. A desktop guide to type 2 diabetes. Diabet Med 1999;16:716-30.
34. 34 American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1999;22 (Suppl. 1): S56-S59.
35. 35 Williams CM. Dietary interventions affecting chylomicron and chylomicron remnant clearance. Atherosclerosis 1998;141 (Suppl. 1):S87-S92.
36. 36 Hardman AE. The influence of exercise on postprandial triacylglycerol metabolism. Atherosclerosis 1998;141 (Suppl. 1): S93-S100.
37. 37 Simpson HS, Williamson CM, Olivecrona T, et al. Postprandial lipemia, fenofibrate and coronary heart disease. Atherosclerosis 1990;85:193-202.
38. 38 Evans LM, Anderson RA, Ogunko AG, et al. Ciprofibrate therapy reduces postprandial lipaemia and improves endothelial function in NIDDM. American Diabetes Association 59th Scientific Session. Abstract 0564., 1999.
39. 39 Durrington PN. Triglycerides are more important in atherosclerosis than epidemiology has suggested. Atherosclerosis 1998;141 (Suppl. 1):S57-S62.
40. 40 Hanefeld M, Temelkova-Kurktschiev T, Kohler C. Effect of oral antidiabetics and insulin on lipids and coronary heart disease in non-insulin dependent diabetes. Ann NY Acad Sci 1997;827:246-68.
41. 41 Goke B, Herrmann-Rinke C. The evolving role of α-glucosidase inhibitors. Diabetes Metab Rev 1998;14:S31-S38.
42. 42 Lebovitz HE. Alpha-glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998;6:132-45.
43. 43 Monnier L. The role of blood glucose-lowering drugs in the light of the UKPDS. Diabetes, Obes Metab 1999;1 (Suppl. 2):S14-S23.
44. 44 Johnston PS, Coniff RF, Hoogwerf BJ, et al. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care 1994;17:20-9.
45. 45 Kennedy FP, Miles JM, Heiling V, et al. The effect of two new alpha-glucosidase inhibitors on metabolic responses to a mixed meal in normal volunteers. Clin Exp Pharmacol Physiol 1987;14:633-40.
46. 46 Johnston PS, Feig PU, Coniff RF, et al. Chronic tretment of African-American type 2 diabetic patients with alpha-glucosidase inhibition. Diabetes Care 1998;21:416-22.
47. 47 Segal P, Feig PU, Schernthaner G, et al. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care 1997;20:687-91.
48. 48 Hanefeld M, Fischer S, Schulze J, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991;14:732-7.
49. 49 Rybka J, Goke B, Sissman J. European comparative study of 2 alpha-glucosidase inhibitors, miglitol and acarbose. [Abstract] ADA, 1999.
50. 50 Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments. Drugs 1997;54:355-68.
51. 51 Howlett HCS, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Safety 1999;20:489-503.
52. 52 Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 1997;20:925-8.
53. 53 Gilbert RE, Cooper ME, Krum H. Drug administration in patients with diabetes mellitus. Safety considerations. Drug Safety 1998;18:441-55.
54. 54 Johnston PS, Lebovitz HE, Coniff RF, et al. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998;83: 1515-22.